PMC10324972_01
Therapy schedule of liposomal honokiol.
fneur-14-1172860-g0001.jpg
PMC10324972_01_fneur-14-1172860-g0001.jpg
F1
The therapy schedule is shown in Figure 1.
MRI images of the patient on 3rd March (A), 21st May (B), 4th August (C), and 15th November (D) 2021.
fneur-14-1172860-g0002.jpg
PMC10324972_01_fneur-14-1172860-g0002.jpg
F2
A new brain MRI after more than 2 months of therapy, on 21 May 2021, demonstrated no significant change in the lesion size in the left frontal lobe (Figure 2). On 4 August 2021, a follow-up craniocerebral MRI showed a mixed signal shadow and a pronounced surrounding edema in the left frontal lobe, while a T1-CE image showed a ring enhancement (Figure 2C). On 15 November, the patient was given bevacizumab combined with etoposide and carboplatin because of another tumor progression (Figure 2D).
Brain biopsy of the patient (A). The H&E staining of the same site (B).
fneur-14-1172860-g0003.jpg
PMC10324972_01_fneur-14-1172860-g0003.jpg
F3
Lesions were found in the frontal lobe, temporal lobe, and bilateral callosum (Figure 3A). On H&E staining, all lesions demonstrated the classic appearance of GBM, including nuclear atypia, palisading necrosis, and microvascular proliferation (Figure 3B).
Immunohistochemical stains of the patient's brain.
fneur-14-1172860-g0004.jpg
PMC10324972_01_fneur-14-1172860-g0004.jpg
F4
Moreover, a high Ki-67 expression (30%) was found in the tumor region (Figure 4).